Senescent Heart Cells Recruit Killer Immune Cells After Heart Attack via CCL8
P16+ senescent fibroblasts and macrophages hijack immune signaling post-infarction, driving deadly cardiac remodeling through a newly identified CCL8 pathway.
Summary
After a heart attack, cells expressing the senescence marker P16 — particularly fibroblasts and macrophages — release a signaling molecule called CCL8 that attracts cytotoxic CD8+ T cells and natural killer cells into the heart. These immune cells then trigger cardiomyocyte death and worsen cardiac remodeling. Using mouse models, researchers showed that blocking CCL8, eliminating P16+ cells with the senolytic combination dasatinib and quercetin, or genetically ablating P16+ fibroblasts each reduced immune infiltration, decreased heart cell death, and improved cardiac function. The findings identify a senescence-driven immune axis as a key mechanism of post-infarction damage and highlight CCL8 and P16+ fibroblasts as promising therapeutic targets.
Detailed Summary
Heart attacks remain a leading cause of death globally, and much of the long-term damage occurs not during the initial event but during the weeks of inflammatory remodeling that follow. Understanding which cell types drive this maladaptive process is critical for developing effective therapies.
This study focused on cells expressing P16 — a well-established molecular marker of cellular senescence — in the heart after myocardial infarction. Using sophisticated reporter mouse models, the researchers mapped which cardiac cell types become P16-positive after ischemic injury: fibroblasts, macrophages, coronary endothelial cells, and cardiomyocytes all showed P16 induction.
Transcriptomic profiling of sorted P16+ cells revealed that fibroblasts and macrophages were the dominant producers of CCL8, a chemokine that recruits cytotoxic lymphocytes. When CCL8 was neutralized or genetically deleted specifically in P16+ cells, fewer CD8+ T cells and natural killer cells infiltrated the heart, cardiomyocyte apoptosis declined, and cardiac repair improved. Notably, ablating P16+ fibroblasts — but not macrophages — reduced fibrosis and restored function, while depleting CD8+ T cells alone was sufficient to attenuate adverse remodeling.
The senolytic drug combination dasatinib and quercetin selectively cleared P16+ macrophages and fibroblasts and similarly improved outcomes, reinforcing the therapeutic value of targeting senescent cells.
These findings establish a mechanistic link between cellular senescence and cytotoxic immunity in ischemic heart disease — a previously underappreciated axis. Clinically, the results suggest that senolytics, CCL8 blockade, or targeted elimination of P16+ fibroblasts could reduce post-infarction damage. Caveats include the preclinical mouse-only design and the complexity of translating intersectional genetic tools to human therapeutics.
Key Findings
- P16+ fibroblasts and macrophages are the primary sources of CCL8 after myocardial infarction in mice.
- CCL8 blockade reduced CD8+ T cell and NK cell infiltration, cut cardiomyocyte apoptosis, and improved heart function.
- Senolytic treatment (dasatinib + quercetin) selectively cleared P16+ macrophages and fibroblasts, improving cardiac outcomes.
- Ablating P16+ fibroblasts — not macrophages — was the key driver of reduced fibrosis and functional recovery.
- CD8+ T cell depletion alone was sufficient to attenuate adverse post-infarction cardiac remodeling.
Methodology
Researchers used p16-CreER;R26-tdT reporter mice to track P16+ cell populations after myocardial infarction, with bulk and single-cell RNA sequencing to identify CCL8 as a key secreted factor. Functional validation involved CCL8 neutralization, Ccl8 conditional knockout in P16+ cells, lymphocyte depletion, and dual-recombinase intersectional genetic ablation of P16+ fibroblasts or macrophages.
Study Limitations
All experiments were conducted in mouse models, and the genetic tools used for cell-type-specific ablation are not directly translatable to human treatment. The study relies on abstract-level data only, so full mechanistic nuances, dosing details, and long-term safety data require review of the complete manuscript.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.